O
Oruka Therapeutics, Inc. (ORKA)
NGM – Real Time Price. Currency in USD
90.60
+3.97 (4.58%)
At close: Jun 26, 2026, 4:00 PM EDT
90.58
-0.02 (-0.02%)
After-hours: Jun 26, 2026, 7:34 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
90.60
+3.97 (4.58%)
At close: Jun 26, 2026, 4:00 PM EDT
90.58
-0.02 (-0.02%)
After-hours: Jun 26, 2026, 7:34 PM EDT
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
| Name | Position |
|---|---|
| Dr. Joana Goncalves M.D. | Chief Medical Officer |
| Dr. Lawrence Otto Klein Ph.D. | President, CEO & Director |
| Dr. Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls |
| Mr. Alan Lada | VP of IR & Capital Markets |
| Mr. Arjun Agarwal CPA | Senior VP of Finance & Treasurer |
| Mr. Christopher Finch | Senior VP and Head of Business Development & Strategy |
| Mr. Paul T. Quinlan | General Counsel & Secretary |
| Ms. Laura Sandler | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-04 | 8-K | ea0293648-8k_oruka.htm |
| 2026-06-01 | 8-K | ea0292876-8k_oruka.htm |
| 2026-05-13 | 10-Q | ea0287752-10q_oruka.htm |
| 2026-04-30 | 8-K | ea0288461-8k_oruka.htm |
| 2026-04-27 | 8-K | ea0287782-8k_oruka.htm |
| 2026-04-17 | DEFA14A | ea0286400-04.htm |
| 2026-04-17 | DEF 14A | ea0286400-01.htm |
| 2026-04-17 | ARS | ea0286400-03.pdf |
| 2026-04-08 | CORRESP | filename1.htm |
| 2026-04-02 | S-3 | ea0284246-s3_oruka.htm |